TGFB1 and breast carcinoma: TGF-β1 [52], TIMP-2 [53], and VEGFR-2 [54] have been recognized in a number of studies as the key regulators of fibrogenesis and angiogenesis, which determined the choice of these biomarkers for detecting the effects of breast cancer treatment.